Richard Bastiani Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Richard Bastiani ARMP stock SEC Form 4 insiders trading

Richard has made over 5 trades of the Armata Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 5,500 units of ARMP stock worth $12,540 on 30 April 2018.

The largest trade he's ever made was exercising 5,500 units of Armata Pharmaceuticals Inc stock on 30 April 2018 worth over $12,540. On average, Richard trades about 2,778 units every 81 days since 2016. As of 30 April 2018 he still owns at least 57,400 units of Armata Pharmaceuticals Inc stock.

You can see the complete history of Richard Bastiani stock trades at the bottom of the page.

Richard Bastiani biography

Richard Bastiani is the Director at Armata Pharmaceuticals Inc.

What's Richard Bastiani's mailing address?

Richard's mailing address filed with the SEC is C/O ARMATA PHARMACEUTICALS, INC., 4503 GLENCOE AVENUE, MARINA DEL REY, CA, 90292.

Insiders trading at Armata Pharmaceuticals Inc

Over the last 6 years, insiders at Armata Pharmaceuticals Inc have traded over $0 worth of Armata Pharmaceuticals Inc stock and bought 24,083,630 units worth $91,149,692 . The most active insiders traders include Inc.Innoviva Strategic Oppo..., Inc. Innoviva,, and Michael S Perry. On average, Armata Pharmaceuticals Inc executives and independent directors trade stock every 122 days with the average trade being worth of $9,151,779. The most recent stock trade was executed by Inc.Innoviva Strategic Oppo... on 31 March 2022, trading 5,385,208 units of ARMP stock currently worth $26,926,040.

What does Armata Pharmaceuticals Inc do?

c3 jian is a well-capitalized, private, los angeles based biotechnology company advancing novel compounds that target unmet medical/dental needs related primarily to oral healthcare. the company's lead compound is a unique peptide drug against dental caries (i.e. tooth decay). the company’s lead compound started fda-regulated phase ii human clinical trials in early 2014. c3 jian's platform technology has also yielded peptides that can affect calcification processes, including not only tooth sensitivity but possibly hair and nail growth as well. the company has recently moved its operations to a new facility in marina del rey. the company was founded based on technology created in the laboratory of dr. wenyuan shi, chair of the department of oral biology at the university of california, los angeles school of dentistry. for more information about the company and to explore career opportunities at c3 jian please visit our webpage at www.c3-jian.com

Armata Pharmaceuticals Inc executives and stock owners

Armata Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Todd R. Patrick MBA,
  Advisor & Director
• Dr. Brian Varnum Ph.D.,
  CEO & Director
• Steven R. Martin,
  Chief Financial Officer
• Robin Kramer,
  Director
• Mina Pastagia,
  Vice President - Clinical Development
• Sarah Schlesinger,
  Director
• Odysseas Kostas,
  Director
• Todd Peterson,
  Director
• Heather Jones,
  Medical Director
• Joseph Patti,
  Director
• Richard Bastiani,
  Director
• Duane Morris,
  Vice President - Operations
• Igor Bilinsky,
  Chief Operating Officer, Senior Vice President
• Steven Martin,
  Chief Financial Officer
• Todd Patrick,
  Chief Executive Officer, Director
• Brian Varnum,
  President, Chief Development Officer
• Erin Butler,
  VP of Fin. & Admin.
• Dr. Mina Pastagia M.D., MS,
  Sr. VP of Clinical Devel.
• Duane Alfred Morris BA,
  VP of Operations
• Dr. Wenyuan Shi Ph.D.,
  Co-Founder & Founding Scientist
• Deborah Birx,
  Chief Executive Officer
• Richard Rychlik,
  Corporate Controller and PFO
• Inc. Innoviva,,
  10% owner
• Richard Bear,
  Director
• Michael S Perry,
  Director
• H Stewart Parker,
  Director
• Jeremy Curnock Cook,
  Director
• Inc.Innoviva Strategic Oppo...,
  
• Jules Haimovitz,
  Director